RhumbLine Advisers
VIRX

RhumbLine Advisers’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

RhumbLine Advisers’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-38,693
Closed -$184K – 3261
2022
Q1 		$184K Buy
38,693
+3,497
+10% +$10.5K ﹤0.01% 2777
2021
Q4 		$128K Sell
35,196
-780
-2% -$4.16K ﹤0.01% 2909
2021
Q3 		$289K Buy
35,976
+5,894
+20% +$58.1K ﹤0.01% 2783
2021
Q2 		$341K Buy
+30,082
New +$302K ﹤0.01% 2735
2015
Q2 		– Sell
-240
Closed -$124K – 3097
2015
Q1 		$124K Buy
240
+44
+22% +$22.2K ﹤0.01% 2928
2014
Q4 		$105K Buy
196
+11
+6% +$4.96K ﹤0.01% 2954
2014
Q3 		$277K Hold
185
– – ﹤0.01% 2575
2014
Q2 		$253K Buy
185
+54
+41% +$62.7K ﹤0.01% 2698
2014
Q1 		$182K Sell
131
-8
-6% -$9.3K ﹤0.01% 2805
2013
Q4 		$138K Sell
139
-5
-3% -$5.17K ﹤0.01% 2919
2013
Q3 		$150K Buy
144
+4
+3% +$4.27K ﹤0.01% 2866
2013
Q2 		$154K Buy
+140
New +$156K ﹤0.01% 3109

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

RhumbLine Advisers's VIRX Position: Q2 2022 in Review

RhumbLine Advisers sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2022, closing a stake of 38,693 shares — an estimated $184K sold.

RhumbLine Advisers first reported a position in VIRX in Q2 2013 and held it in 12 quarters. The position peaked at $341K in Q2 2021. 63 funds tracked by Wall St. Rank hold VIRX as of Q2 2022.

  • RhumbLine Advisers reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • RhumbLine Advisers sold 38,693 Viracta Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $184K.
  • RhumbLine Advisers first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 12 quarters.
  • RhumbLine Advisers's Viracta Therapeutics, Inc. Common Stock position peaked at $341K in Q2 2021.
  • 63 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2022.

Based on RhumbLine Advisers's 13F filing for Q2 2022, filed 11 Aug 2022.